Structure via PubChem · Public domain (PubChem)
granisetron
Sign in to saveAlso known as LY-278584, Kytril, BRL-43694, SID90340785, BRL 43694, Sancuso
Granisetron is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and radiotherapy. Its main effect is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors.
Key facts
- Drug.legal_AU
- S4
- Drug.licence_EU
- yes
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 461123553
- Drug.IUPAC_name
- 1-Methyl-N-((1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-1H-indazole-3-carboxamide
- Drug.image
- Granisetron structure.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 185
- Drug.image2
- Granisetron_3D.png
- Drug.tradename
- Kytril, Sancuso, others
- Drug.MedlinePlus
- a601211
- Drug.pregnancy_AU
- B1
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_UK
- POM
- Drug.routes_of_administration
- By mouth, intravenous, transdermal
- Drug.bioavailability
- 60%
via Wikipedia infobox
Chemical data
- Formula
- C18H24N4O
- Molecular weight
- 312.4 g/mol
- IUPAC name
- 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide
- SMILES
- CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C
- InChIKey
- MFWNKCLOYSRHCJ-UHFFFAOYSA-N
- XLogP
- 2.8
- Polar surface area
- 50.2 Ų
- H-bond donors
- 1
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Research
1,906 papers- Transdermal granisetron.Drugs · 2009
- Granisetron.Connecticut medicine · 1995
- Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) - is there still a role after comparison with palonosetron?Expert opinion on pharmacotherapy · 2017
- Granisetron: relating pharmacology to clinical efficacy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2003
- Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting.Drugs · 2016
via PubMed
Wikidata facts
- Mass
- 312.195011
Show 6 more facts
- Commons category
- Granisetron
- chemical formula
- C₁₈H₂₄N₄O
- canonical SMILES
- CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C
- isomeric SMILES
- CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C4=C1C=CC=C4
- NCI Thesaurus ID
- C62031
- defined daily dose
- 3
via Wikidata · CC0
~3 min read
Article
9 sectionsContents
- Medical uses
- Chemotherapy
- Post operative
- Gastroparesis
- Other
- Adverse effects
- Extended release
- References
- Further reading
Granisetron is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and radiotherapy. Its main effect is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors.
Granisetron was developed by chemists working at the British drug company Beecham and is available as a generic. It is produced by Roche Laboratories under the trade name Kytril. The drug was approved in the United Kingdom in 1991 and in United States in 1994 by the FDA.